Clinical Trial

International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma

Study acronym: LBL 2018
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Primary objectives: * Randomization R1, all patients eligible: To examine, whether the cumulative incidence of relapses with involvement of the CNS (CNS relapse, pCICR) can be decreased by a modified induction therapy including dexamethasone (experimental arm) instead of prednisone (standard arm) * Randomization R2, only patients with high risk LBL eligible: to examine, whether the probability of event-free survival (pEFS) in these patients can be improved by receiving an intensified treatment arm versus a standard treatment arm (as used in the EURO-LB 02)
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2019-07-31; most recent amendment 2026-04-29.
Status change: Not Yet Recruiting → Recruiting 2019-09-04
Trial Details
NCT Number NCT04043494
Lead Sponsor University Hospital Muenster
Collaborators: Deutsche Krebshilfe e.V., Bonn (Germany)
Conditions Lymphoblastic Lymphoma, Childhood
Enrollment 683 participants
Start Date 2019-08-23
Primary Completion 2030-04-22 (estimated)
Study Completion 2030-04-22 (estimated)
Updated on ClinicalTrials.gov 2026-05-06